Miltenyi Biomedicine GmbH
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-30
RECRUITING8
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO33%
Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.6 months). See all sponsors →
Open Miltenyi Biomedicine GmbH on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| DALY 2-EU NCT04844866 |
P2 | Recruiting | Diffuse Large B-cell Lymphoma | 213 | 2025-01-15 |
| CASTLE NCT06347718 |
P1/2 | Recruiting | Systemic Lupus Erythematosus; Systemic Sclerosis | 24 | 2026-05-31 |
| zamtocabtagene autoleucel (MB-CART2019.1) NCT04792489 |
P2 | Recruiting | Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma | 315 | 2026-12-31 (+56 mo) |
| DALY II Japan NCT07288879 |
P2 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma; CAR T Cell Therapy | 31 | 2027-01-31 |
| MB-CART19.1 NCT06189157 |
P1/2 | Recruiting | SLE - Systemic Lupus Erythematosus | 29 | 2027-09-30 (+31 mo) |
| MB-dNPM1-TCR.1 NCT06424340 |
P1/2 | Recruiting | Leukemia, Myeloid, Acute | 29 | 2028-06 |
| FRONTIER NCT07569965 |
P2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 52 | 2029-09 |
| DALY PED NCT06508931 |
P2 | Recruiting | B-Cell Neoplasm | 31 | 2029-12-31 (+3 mo) |
| MB-CART2019.1 NCT07178431 |
P1/2 | Recruiting | Multiple Sclerosis; CAR T Cell Therapy | 26 | 2030-08-16 (+6 mo) |